- Home
- BRNS vs CFSB Comparison
BRNS vs CFSB Comparison
Compare BRNS & CFSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- CFSB
- Stock Information
- Founded
- BRNS 2016
- CFSB 1889
- Country
- BRNS United Kingdom
- CFSB United States
- Employees
- BRNS N/A
- CFSB N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- CFSB Major Banks
- Sector
- BRNS Health Care
- CFSB Finance
- Exchange
- BRNS Nasdaq
- CFSB Nasdaq
- Market Cap
- BRNS 41.0M
- CFSB 44.9M
- IPO Year
- BRNS 2021
- CFSB N/A
- Fundamental
- Price
- BRNS $1.04
- CFSB $6.94
- Analyst Decision
- BRNS Strong Buy
- CFSB
- Analyst Count
- BRNS 2
- CFSB 0
- Target Price
- BRNS $3.00
- CFSB N/A
- AVG Volume (30 Days)
- BRNS 46.0K
- CFSB 5.6K
- Earning Date
- BRNS 11-06-2024
- CFSB 01-28-2025
- Dividend Yield
- BRNS N/A
- CFSB N/A
- EPS Growth
- BRNS N/A
- CFSB N/A
- EPS
- BRNS N/A
- CFSB N/A
- Revenue
- BRNS $14,969,000.00
- CFSB $7,444,000.00
- Revenue This Year
- BRNS $1,805.74
- CFSB N/A
- Revenue Next Year
- BRNS N/A
- CFSB N/A
- P/E Ratio
- BRNS N/A
- CFSB N/A
- Revenue Growth
- BRNS 106.21
- CFSB N/A
- 52 Week Low
- BRNS $0.80
- CFSB $6.34
- 52 Week High
- BRNS $4.16
- CFSB $7.95
- Technical
- Relative Strength Index (RSI)
- BRNS 48.42
- CFSB 65.50
- Support Level
- BRNS $0.91
- CFSB $6.80
- Resistance Level
- BRNS $1.15
- CFSB $6.94
- Average True Range (ATR)
- BRNS 0.15
- CFSB 0.04
- MACD
- BRNS -0.01
- CFSB 0.01
- Stochastic Oscillator
- BRNS 34.96
- CFSB 100.00
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
About CFSB CFSB Bancorp Inc.
CFSB Bancorp Inc provides banking services. It offers a variety of financial services to individuals and small businesses through its offices in Quincy, Holbrook, and Weymouth. Its primary deposit products are savings, checking, and term certificate accounts, and its primary lending product is residential mortgage loans.The Company's loan portfolio includes residential real estate, commercial real estate, construction, and consumer loan segments. Residential real estate loans include classes for one- to four-family, multi-family, second mortgages and home equity lines of credit.